Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

Go back to Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

Needham on Medtronic, Inc. (MDT): 'We believe that MDT is in the early stages of a strong product cycle'

September 1, 2026 1:27 PM EDT

Needham analyst Michael Matson reiterated a Buy rating and $114.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "MDT's F1Q27 revenue and EPS beat consensus, and management raised FY27 revenue and EPS guidance. Organic growth improved to 7.0%... More

Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance

September 1, 2026 6:47 AM EDT

Medtronic (NYSE: MDT) reported Q1 EPS of $1.45, $0.06 better than the analyst estimate of $1.39. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.55 billion.

GUIDANCE:

Medtronic sees FY2027 EPS of $5.94-$6.00, versus the consensus of $5.95.

For earnings history and earnings-related data on Medtronic (MDT) click here.

... More